The post Oracle and M42 Collaborate to Enhance Healthcare with Genomic Insights appeared on BitcoinEthereumNews.com. Rebeca Moen Nov 03, 2025 04:19 Oracle Health and M42 are partnering to integrate genomic data into healthcare records, aiming to provide personalized treatments and improve disease prevention across the UAE. Oracle Health has announced a strategic partnership with M42, a leader in global health innovation, to harness the power of genomics in healthcare. This collaboration aims to advance the delivery of precision medicine through the integration of pharmacogenomic data at the point of care, according to Oracle. Advancing Precision Medicine The partnership will focus on creating unified, longitudinal patient records accessible throughout the UAE. This initiative will see Oracle Health and M42 incorporating data from the Emirati Genome Program directly into electronic health records (EHR). This integration aims to support personalized, data-driven healthcare by enabling pharmacogenomic recommendations for patients, thereby optimizing treatment outcomes and improving overall healthcare delivery. Empowering Clinicians and Patients Dimitris Moulavasilis, Group CEO at M42, emphasized the transformative potential of this collaboration, stating that it will empower clinicians with actionable insights and allow for proactive, personalized care. He highlighted the goal of shaping a healthier future for communities across the UAE by making healthcare predictive and accessible. Dr. Fahed Al Marzooqi, CEO of M42’s Integrated Health Solutions platform, noted the importance of informing physicians at the point of prescribing about genetic compatibility with medications. This capability is expected to enhance the effectiveness of prescribed treatments and expedite patient recovery. Strategic Objectives and Benefits The collaboration, formalized during a signing ceremony, aims to revolutionize healthcare delivery both nationally and beyond. Key objectives include: Proactive Healthcare: Utilizing AI and advanced analytics to shift the focus from reactive care to preventive measures, thereby promoting longevity and well-being. Precision Medicine at Scale: Leveraging genomic data to provide tailored treatments, reinforcing the UAE’s… The post Oracle and M42 Collaborate to Enhance Healthcare with Genomic Insights appeared on BitcoinEthereumNews.com. Rebeca Moen Nov 03, 2025 04:19 Oracle Health and M42 are partnering to integrate genomic data into healthcare records, aiming to provide personalized treatments and improve disease prevention across the UAE. Oracle Health has announced a strategic partnership with M42, a leader in global health innovation, to harness the power of genomics in healthcare. This collaboration aims to advance the delivery of precision medicine through the integration of pharmacogenomic data at the point of care, according to Oracle. Advancing Precision Medicine The partnership will focus on creating unified, longitudinal patient records accessible throughout the UAE. This initiative will see Oracle Health and M42 incorporating data from the Emirati Genome Program directly into electronic health records (EHR). This integration aims to support personalized, data-driven healthcare by enabling pharmacogenomic recommendations for patients, thereby optimizing treatment outcomes and improving overall healthcare delivery. Empowering Clinicians and Patients Dimitris Moulavasilis, Group CEO at M42, emphasized the transformative potential of this collaboration, stating that it will empower clinicians with actionable insights and allow for proactive, personalized care. He highlighted the goal of shaping a healthier future for communities across the UAE by making healthcare predictive and accessible. Dr. Fahed Al Marzooqi, CEO of M42’s Integrated Health Solutions platform, noted the importance of informing physicians at the point of prescribing about genetic compatibility with medications. This capability is expected to enhance the effectiveness of prescribed treatments and expedite patient recovery. Strategic Objectives and Benefits The collaboration, formalized during a signing ceremony, aims to revolutionize healthcare delivery both nationally and beyond. Key objectives include: Proactive Healthcare: Utilizing AI and advanced analytics to shift the focus from reactive care to preventive measures, thereby promoting longevity and well-being. Precision Medicine at Scale: Leveraging genomic data to provide tailored treatments, reinforcing the UAE’s…

Oracle and M42 Collaborate to Enhance Healthcare with Genomic Insights

2025/11/04 12:26


Rebeca Moen
Nov 03, 2025 04:19

Oracle Health and M42 are partnering to integrate genomic data into healthcare records, aiming to provide personalized treatments and improve disease prevention across the UAE.

Oracle Health has announced a strategic partnership with M42, a leader in global health innovation, to harness the power of genomics in healthcare. This collaboration aims to advance the delivery of precision medicine through the integration of pharmacogenomic data at the point of care, according to Oracle.

Advancing Precision Medicine

The partnership will focus on creating unified, longitudinal patient records accessible throughout the UAE. This initiative will see Oracle Health and M42 incorporating data from the Emirati Genome Program directly into electronic health records (EHR). This integration aims to support personalized, data-driven healthcare by enabling pharmacogenomic recommendations for patients, thereby optimizing treatment outcomes and improving overall healthcare delivery.

Empowering Clinicians and Patients

Dimitris Moulavasilis, Group CEO at M42, emphasized the transformative potential of this collaboration, stating that it will empower clinicians with actionable insights and allow for proactive, personalized care. He highlighted the goal of shaping a healthier future for communities across the UAE by making healthcare predictive and accessible.

Dr. Fahed Al Marzooqi, CEO of M42’s Integrated Health Solutions platform, noted the importance of informing physicians at the point of prescribing about genetic compatibility with medications. This capability is expected to enhance the effectiveness of prescribed treatments and expedite patient recovery.

Strategic Objectives and Benefits

The collaboration, formalized during a signing ceremony, aims to revolutionize healthcare delivery both nationally and beyond. Key objectives include:

  • Proactive Healthcare: Utilizing AI and advanced analytics to shift the focus from reactive care to preventive measures, thereby promoting longevity and well-being.
  • Precision Medicine at Scale: Leveraging genomic data to provide tailored treatments, reinforcing the UAE’s leadership in personalized healthcare.
  • Nationwide Access: Developing a secure, scalable patient portal for seamless access to health records, enhancing care coordination and patient engagement.

Enhancing Treatment Efficacy

Seema Verma, Executive Vice President at Oracle Health and Life Sciences, highlighted the role of pharmacogenomic insights in delivering more personalized care. By tailoring medications to a patient’s genetic profile, the initiative aims to enhance treatment efficacy, improve preventive care, and reduce the waste associated with ineffective prescriptions. This aligns with the UAE’s vision of pioneering health innovation and delivering exceptional, patient-centric care.

The Emirati Genome Program, one of the world’s largest genomic initiatives, plays a crucial role in this endeavor by advancing disease prevention and enabling early diagnosis and personalized treatments based on local genetic profiles.

Image source: Shutterstock

Source: https://blockchain.news/news/oracle-m42-collaborate-enhance-healthcare-genomic-insights

Тәуекелдер туралы ескертпе: Бұл сайтта жарияланған мақалалар қоғамдық платформалардан алынған және тек ақпараттық мақсатта ұсынылады. Олар міндетті түрде MEXC көзқарасын білдірмейді. Барлық құқықтар бастапқы авторларға тиесілі. Егер қандай да бір мазмұн үшінші тараптың құқықтарын бұзады деп ойласаңыз, оны жою үшін service@support.mexc.com мекенжайына хабарласыңыз. MEXC мазмұнның нақтылығы, толықтығы немесе өзектілігіне кепілдік бермейді және ұсынылған ақпарат негізінде жасалған кез келген әрекет үшін жауапты емес. Бұл мазмұн қаржылық, заңдық немесе басқа кәсіби кеңес болып саналмайды және MEXC тарапынан ұсыныс немесе мақұлдау ретінде қабылданбауы тиіс.

Мыналар да ұнауы мүмкін

Slate Milk Raises $23 Million Series B Round To Bolster Protein Drink’s Rapid Growth

Slate Milk Raises $23 Million Series B Round To Bolster Protein Drink’s Rapid Growth

The post Slate Milk Raises $23 Million Series B Round To Bolster Protein Drink’s Rapid Growth appeared on BitcoinEthereumNews.com. Slate Classic Chocolate milk shake Slate A new slate of functional beverages is about to dominate the ready-to-drink shelf, ushering in a more modern era of easily incorporating more protein in our diets. Today, Slate Milk cofounders Manny Lubin and Josh Belinsky reveal the brand has raised a $23 million Series B funding round. Led by Foundership, a new fund by Yasso frozen greek yogurt cofounders Drew Harrington and Amanda Klane, the money will allow Slate to continue its momentum towards ubiquity as it hits 100,000 points of distribution across 20,000 stores nationwide by the end of 2025. Slate also reveals that it is rolling out several line extensions including a 20 gram protein Strawberry milk at Sprouts Farmers Market, a 30 gram protein Cookies & Cream milk at Target, and a 30 gram protein Salted Caramel flavor at Walmart and Albertsons banner stores. New “Ultra” 42 gram protein options in Chocolate, Vanilla and Salted Caramel will also be available in retailers across the country. “Stores where we may have just had our ready-to-drink lattes, now we’re adding our shakes, and vice versa. We’re adding new partners and executing deeper with our existing partners,” Lubin tells me. The impressive growth is due to Slate’s early entry into the high-protein product space slightly before it caught mainstream attention–ready to execute immediately once consumers craved it most. Slate’s macronutrient ratios are practically unbeatable, largely due to the utilization of ultra-filtered milk. It’s a protein drink that writes a new script about who protein drinks are for. “We’re not sons of dairy farmers. We had no milk history,” Lubin says “We’re just a couple of dudes from the burbs of Boston who like chocolate milk.” Slate cofounder Manny Lubin Slate Another Clean Slate Slate’s brand has evolved significantly in just the past six…
Бөлісу
BitcoinEthereumNews2025/09/19 03:08